Analysis of Profitability Ratios
Quarterly Data
Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
AbbVie Inc., profitability ratios (quarterly data)
Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | AbbVie Inc. gross profit margin ratio improved from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022. |
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | AbbVie Inc. operating profit margin ratio improved from Q4 2021 to Q1 2022 but then deteriorated significantly from Q1 2022 to Q2 2022. |
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | AbbVie Inc. net profit margin ratio improved from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022. |
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | AbbVie Inc. ROE improved from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022. |
| ROA | A profitability ratio calculated as net income divided by total assets. | AbbVie Inc. ROA improved from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022. |
Gross Profit Margin
AbbVie Inc., gross profit margin calculation (quarterly data)
| Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Gross margin | 10,413 | 9,486 | 10,566 | 9,952 | 9,436 | 8,797 | 9,174 | 7,852 | 6,714 | 6,677 | 6,698 | 6,559 | 6,436 | 6,134 | 6,283 | 6,401 | 6,344 | 6,007 | 5,459 | 5,379 | 5,416 | 4,922 | |||||||
| Net revenues | 14,583 | 13,538 | 14,886 | 14,342 | 13,959 | 13,010 | 13,858 | 12,902 | 10,425 | 8,619 | 8,704 | 8,479 | 8,255 | 7,828 | 8,305 | 8,236 | 8,278 | 7,934 | 7,739 | 6,995 | 6,944 | 6,538 | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| Gross profit margin1 | 70.48% | 69.53% | 68.96% | 67.72% | 65.62% | 64.82% | 66.41% | 68.74% | 73.56% | 77.43% | 77.64% | 77.32% | 77.41% | 77.07% | 76.44% | 75.22% | 74.93% | 75.18% | 75.05% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
| Amgen Inc. | 74.00% | 73.30% | 73.44% | 74.00% | 73.97% | 74.37% | 74.59% | 75.55% | 77.15% | 78.90% | 80.38% | 81.19% | 81.23% | 81.26% | 81.80% | 81.61% | 81.78% | 81.69% | 81.33% | — | — | — | |||||||
| Eli Lilly & Co. | 75.98% | 74.40% | 74.18% | 74.85% | 74.27% | 75.88% | 77.66% | 78.26% | 78.67% | 79.22% | 78.85% | 77.78% | 76.67% | 74.96% | 73.81% | 73.39% | 72.92% | 72.95% | 73.46% | — | — | — | |||||||
| Johnson & Johnson | 67.86% | 67.97% | 68.16% | 67.51% | 67.00% | 66.24% | 65.58% | 65.68% | 65.66% | 66.15% | 66.42% | 66.49% | 66.67% | 66.80% | 66.79% | 66.36% | 65.69% | 66.22% | 66.84% | — | — | — | |||||||
| Merck & Co. Inc. | 70.41% | 70.72% | 72.02% | 67.95% | 67.48% | 66.99% | 67.74% | 71.23% | 70.06% | 70.11% | 69.87% | 70.13% | 69.89% | 68.94% | 68.06% | 67.35% | 67.81% | 68.22% | 68.16% | — | — | — | |||||||
| Moderna Inc. | 81.66% | 84.26% | 85.19% | 84.71% | 84.49% | 89.60% | 96.03% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 62.18% | 60.35% | 62.08% | 65.25% | 70.96% | 76.46% | 79.26% | 80.47% | 80.19% | 80.03% | 80.25% | 79.85% | 79.91% | 79.36% | 79.03% | 78.58% | 78.24% | 78.48% | 78.61% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 84.97% | 84.65% | 84.83% | 86.65% | 86.85% | 86.84% | 86.82% | 87.98% | 88.21% | 89.72% | 90.05% | 91.14% | 92.27% | 92.79% | 93.53% | 93.36% | 93.28% | 92.95% | 93.24% | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 46.63% | 48.37% | 50.08% | 51.05% | 51.29% | 51.47% | 49.67% | 47.31% | 45.39% | 44.30% | 44.35% | 44.48% | 44.51% | 44.60% | 44.57% | 44.36% | 44.55% | 44.68% | 45.15% | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q2 2022 Calculation
Gross profit margin = 100
× (Gross marginQ2 2022
+ Gross marginQ1 2022
+ Gross marginQ4 2021
+ Gross marginQ3 2021)
÷ (Net revenuesQ2 2022
+ Net revenuesQ1 2022
+ Net revenuesQ4 2021
+ Net revenuesQ3 2021)
= 100 × (10,413 + 9,486 + 10,566 + 9,952)
÷ (14,583 + 13,538 + 14,886 + 14,342)
= 70.48%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | AbbVie Inc. gross profit margin ratio improved from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022. |
Operating Profit Margin
AbbVie Inc., operating profit margin calculation (quarterly data)
| Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Operating earnings | 3,295 | 4,717 | 5,074 | 4,306 | 4,441 | 4,103 | 3,753 | 3,255 | 752 | 3,603 | 3,956 | 2,617 | 3,400 | 3,010 | (2,441) | 3,159 | 2,762 | 2,903 | 1,794 | 2,705 | 2,674 | 2,419 | |||||||
| Net revenues | 14,583 | 13,538 | 14,886 | 14,342 | 13,959 | 13,010 | 13,858 | 12,902 | 10,425 | 8,619 | 8,704 | 8,479 | 8,255 | 7,828 | 8,305 | 8,236 | 8,278 | 7,934 | 7,739 | 6,995 | 6,944 | 6,538 | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| Operating profit margin1 | 30.33% | 32.68% | 31.89% | 30.09% | 28.95% | 23.63% | 24.81% | 28.45% | 30.17% | 39.86% | 39.03% | 20.04% | 21.85% | 19.88% | 19.49% | 32.99% | 32.84% | 34.03% | 33.99% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
| Amgen Inc. | 38.04% | 32.78% | 31.44% | 30.14% | 30.72% | 37.23% | 37.70% | 38.59% | 39.76% | 41.89% | 43.57% | 44.83% | 44.05% | 44.53% | 45.55% | 45.82% | 46.46% | 46.07% | 45.76% | — | — | — | |||||||
| Eli Lilly & Co. | 25.50% | 25.94% | 22.45% | 23.17% | 21.81% | 22.06% | 24.69% | 23.55% | 24.48% | 25.64% | 22.29% | 20.00% | 19.48% | 12.50% | 15.15% | 12.34% | 9.11% | 14.88% | 9.38% | — | — | — | |||||||
| Johnson & Johnson | 23.47% | 23.76% | 24.95% | 24.69% | 25.23% | 24.10% | 23.60% | 24.30% | 24.64% | 25.62% | 24.15% | 24.15% | 22.63% | 22.69% | 24.27% | 22.59% | 23.05% | 23.63% | 24.07% | — | — | — | |||||||
| Merck & Co. Inc. | 33.04% | 28.85% | 25.74% | 14.07% | 10.64% | 14.02% | 16.47% | 26.87% | 25.40% | 25.49% | 24.77% | 25.56% | 26.73% | 24.38% | 19.62% | 17.84% | 12.28% | 13.57% | 16.28% | — | — | — | |||||||
| Moderna Inc. | 70.46% | 74.34% | 75.22% | 69.57% | 62.28% | 32.79% | -381.82% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 30.37% | 26.12% | 23.91% | 24.64% | 24.12% | 21.20% | 19.47% | 21.17% | 21.17% | 24.20% | 25.46% | 26.30% | 27.50% | 26.86% | 26.10% | 26.18% | 26.00% | 25.86% | 25.92% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 48.19% | 55.08% | 55.67% | 55.19% | 53.94% | 43.37% | 42.09% | 37.43% | 34.64% | 30.45% | 28.10% | 29.55% | 29.58% | 35.41% | 37.77% | 37.00% | 36.89% | 36.54% | 35.41% | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 22.51% | 23.83% | 25.57% | 27.04% | 28.00% | 27.68% | 24.19% | 20.90% | 17.05% | 17.86% | 17.99% | 17.88% | 18.00% | 15.90% | 15.53% | 15.03% | 14.36% | 14.23% | 14.19% | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q2 2022 Calculation
Operating profit margin = 100
× (Operating earningsQ2 2022
+ Operating earningsQ1 2022
+ Operating earningsQ4 2021
+ Operating earningsQ3 2021)
÷ (Net revenuesQ2 2022
+ Net revenuesQ1 2022
+ Net revenuesQ4 2021
+ Net revenuesQ3 2021)
= 100 × (3,295 + 4,717 + 5,074 + 4,306)
÷ (14,583 + 13,538 + 14,886 + 14,342)
= 30.33%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | AbbVie Inc. operating profit margin ratio improved from Q4 2021 to Q1 2022 but then deteriorated significantly from Q1 2022 to Q2 2022. |
Net Profit Margin
AbbVie Inc., net profit margin calculation (quarterly data)
| Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Net earnings (loss) attributable to AbbVie Inc. | 924 | 4,490 | 4,044 | 3,179 | 766 | 3,553 | 36 | 2,308 | (738) | 3,010 | 2,801 | 1,884 | 741 | 2,456 | (1,826) | 2,747 | 1,983 | 2,783 | 52 | 1,631 | 1,915 | 1,711 | |||||||
| Net revenues | 14,583 | 13,538 | 14,886 | 14,342 | 13,959 | 13,010 | 13,858 | 12,902 | 10,425 | 8,619 | 8,704 | 8,479 | 8,255 | 7,828 | 8,305 | 8,236 | 8,278 | 7,934 | 7,739 | 6,995 | 6,944 | 6,538 | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| Net profit margin1 | 22.04% | 22.00% | 20.54% | 13.66% | 12.40% | 10.28% | 10.08% | 18.16% | 19.20% | 24.77% | 23.69% | 9.90% | 12.62% | 16.42% | 17.36% | 23.50% | 20.84% | 21.55% | 18.82% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
| Amgen Inc. | 26.73% | 23.42% | 24.25% | 23.03% | 23.80% | 29.60% | 29.97% | 30.91% | 31.53% | 33.64% | 35.32% | 36.14% | 35.57% | 35.93% | 37.25% | 9.96% | 10.72% | 10.11% | 9.08% | — | — | — | |||||||
| Eli Lilly & Co. | 19.58% | 20.90% | 19.71% | 21.52% | 22.71% | 23.91% | 25.24% | 24.01% | 24.48% | 23.97% | 37.27% | 35.10% | 33.76% | 26.12% | 13.16% | 1.85% | -0.60% | 4.82% | -0.89% | — | — | — | |||||||
| Johnson & Johnson | 19.21% | 20.90% | 22.26% | 19.55% | 19.92% | 17.95% | 17.82% | 21.01% | 18.86% | 20.75% | 18.42% | 17.32% | 20.08% | 17.99% | 18.75% | 1.89% | 1.70% | 1.58% | 1.70% | — | — | — | |||||||
| Merck & Co. Inc. | 29.00% | 26.27% | 26.79% | 15.09% | 11.83% | 15.09% | 14.72% | 24.33% | 22.20% | 21.10% | 21.01% | 20.26% | 21.10% | 19.50% | 14.71% | 8.02% | 3.25% | 3.88% | 5.97% | — | — | — | |||||||
| Moderna Inc. | 63.31% | 66.94% | 69.04% | 64.55% | 57.01% | 30.95% | -373.77% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 28.94% | 27.01% | 27.04% | 28.74% | 23.86% | 24.03% | 22.95% | 18.59% | 31.31% | 32.32% | 31.45% | 30.57% | 23.58% | 21.31% | 20.79% | 44.63% | 42.35% | 41.29% | 40.55% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 39.97% | 48.06% | 50.25% | 51.65% | 50.11% | 43.53% | 41.35% | 38.28% | 37.30% | 28.56% | 26.91% | 28.13% | 28.59% | 35.12% | 36.42% | 28.24% | 25.65% | 23.54% | 20.41% | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 17.37% | 18.49% | 19.70% | 21.93% | 22.47% | 22.08% | 19.79% | 17.12% | 14.12% | 14.31% | 14.47% | 14.24% | 14.24% | 12.89% | 12.06% | 10.75% | 10.36% | 10.24% | 10.64% | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q2 2022 Calculation
Net profit margin = 100
× (Net earnings (loss) attributable to AbbVie Inc.Q2 2022
+ Net earnings (loss) attributable to AbbVie Inc.Q1 2022
+ Net earnings (loss) attributable to AbbVie Inc.Q4 2021
+ Net earnings (loss) attributable to AbbVie Inc.Q3 2021)
÷ (Net revenuesQ2 2022
+ Net revenuesQ1 2022
+ Net revenuesQ4 2021
+ Net revenuesQ3 2021)
= 100 × (924 + 4,490 + 4,044 + 3,179)
÷ (14,583 + 13,538 + 14,886 + 14,342)
= 22.04%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | AbbVie Inc. net profit margin ratio improved from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022. |
Return on Equity (ROE)
AbbVie Inc., ROE calculation (quarterly data)
| Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Net earnings (loss) attributable to AbbVie Inc. | 924 | 4,490 | 4,044 | 3,179 | 766 | 3,553 | 36 | 2,308 | (738) | 3,010 | 2,801 | 1,884 | 741 | 2,456 | (1,826) | 2,747 | 1,983 | 2,783 | 52 | 1,631 | 1,915 | 1,711 | |||||||
| Stockholders’ equity (deficit) | 14,653 | 16,283 | 15,408 | 13,550 | 12,569 | 13,710 | 13,076 | 15,270 | 14,708 | (7,415) | (8,172) | (8,226) | (8,566) | (7,826) | (8,446) | (2,921) | (3,375) | 3,553 | 5,097 | 6,687 | 6,009 | 4,998 | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| ROE1 | 86.24% | 76.64% | 74.91% | 55.60% | 53.01% | 37.63% | 35.30% | 48.34% | 47.30% | — | — | — | — | — | — | — | — | 179.59% | 104.16% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||||||||
| Amgen Inc. | 271.85% | 624.78% | 87.96% | 68.26% | 69.67% | 75.91% | 77.20% | 67.09% | 68.48% | 80.92% | 81.07% | 73.83% | 73.73% | 74.55% | 67.15% | 15.35% | 15.86% | 14.21% | 7.84% | — | — | — | |||||||
| Eli Lilly & Co. | 66.61% | 65.69% | 62.16% | 76.99% | 94.20% | 88.31% | 109.79% | 115.45% | 137.26% | 179.72% | 319.09% | 234.97% | 282.08% | 252.24% | 32.88% | 3.44% | -1.24% | 7.74% | -1.76% | — | — | — | |||||||
| Johnson & Johnson | 24.05% | 26.54% | 28.20% | 25.44% | 25.53% | 22.96% | 23.25% | 26.35% | 24.11% | 28.01% | 25.42% | 24.31% | 26.87% | 24.90% | 25.60% | 2.39% | 2.18% | 1.97% | 2.16% | — | — | — | |||||||
| Merck & Co. Inc. | 38.34% | 34.68% | 34.17% | 20.10% | 16.73% | 26.08% | 27.91% | 39.47% | 37.91% | 38.72% | 37.99% | 34.70% | 33.88% | 30.50% | 23.30% | 10.32% | 4.12% | 4.69% | 6.97% | — | — | — | |||||||
| Moderna Inc. | 78.15% | 85.73% | 86.26% | 69.75% | 52.13% | 15.59% | -29.17% | -21.66% | -16.54% | -30.82% | -43.75% | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 33.61% | 30.29% | 28.47% | 26.28% | 18.86% | 16.23% | 15.21% | 12.22% | 22.05% | 24.21% | 25.77% | 24.91% | 21.24% | 19.52% | 17.59% | 33.40% | 32.31% | 29.72% | 29.88% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 27.49% | 39.84% | 43.03% | 40.53% | 41.02% | 33.43% | 31.86% | 31.17% | 32.94% | 18.79% | 19.08% | 20.41% | 21.21% | 25.70% | 27.91% | 22.85% | 22.14% | 21.74% | 19.51% | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 17.59% | 18.56% | 18.94% | 22.13% | 23.32% | 22.60% | 18.47% | 15.33% | 12.41% | 12.85% | 12.45% | 12.24% | 12.33% | 11.46% | 10.65% | 9.55% | 9.05% | 8.62% | 8.76% | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q2 2022 Calculation
ROE = 100
× (Net earnings (loss) attributable to AbbVie Inc.Q2 2022
+ Net earnings (loss) attributable to AbbVie Inc.Q1 2022
+ Net earnings (loss) attributable to AbbVie Inc.Q4 2021
+ Net earnings (loss) attributable to AbbVie Inc.Q3 2021)
÷ Stockholders’ equity (deficit)
= 100 × (924 + 4,490 + 4,044 + 3,179)
÷ 14,653 = 86.24%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | AbbVie Inc. ROE improved from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022. |
Return on Assets (ROA)
AbbVie Inc., ROA calculation (quarterly data)
| Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Net earnings (loss) attributable to AbbVie Inc. | 924 | 4,490 | 4,044 | 3,179 | 766 | 3,553 | 36 | 2,308 | (738) | 3,010 | 2,801 | 1,884 | 741 | 2,456 | (1,826) | 2,747 | 1,983 | 2,783 | 52 | 1,631 | 1,915 | 1,711 | |||||||
| Total assets | 143,186 | 143,211 | 146,529 | 148,858 | 147,972 | 150,501 | 150,565 | 149,621 | 149,530 | 91,199 | 89,115 | 59,441 | 57,142 | 56,769 | 59,352 | 66,164 | 61,641 | 69,342 | 70,786 | 68,840 | 66,994 | 65,664 | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| ROA1 | 8.83% | 8.71% | 7.88% | 5.06% | 4.50% | 3.43% | 3.07% | 4.93% | 4.65% | 9.25% | 8.84% | 5.48% | 7.21% | 9.44% | 9.58% | 11.43% | 10.46% | 9.20% | 7.50% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||||||||
| Amgen Inc. | 11.09% | 9.67% | 9.63% | 8.63% | 9.61% | 11.33% | 11.54% | 11.37% | 11.23% | 12.45% | 13.13% | 13.55% | 13.40% | 12.62% | 12.64% | 3.27% | 3.49% | 3.12% | 2.48% | — | — | — | |||||||
| Eli Lilly & Co. | 12.09% | 13.06% | 11.44% | 12.39% | 12.70% | 13.01% | 13.28% | 12.68% | 13.39% | 13.46% | 21.17% | 20.97% | 20.28% | 16.46% | 7.36% | 1.01% | -0.34% | 2.53% | -0.45% | — | — | — | |||||||
| Johnson & Johnson | 10.33% | 11.12% | 11.47% | 9.98% | 10.07% | 8.76% | 8.41% | 9.95% | 9.59% | 11.07% | 9.59% | 9.10% | 10.53% | 9.78% | 10.00% | 0.99% | 0.88% | 0.79% | 0.83% | — | — | — | |||||||
| Merck & Co. Inc. | 15.48% | 13.29% | 12.35% | 7.70% | 6.14% | 7.73% | 7.72% | 12.83% | 11.56% | 11.95% | 11.66% | 11.18% | 11.15% | 10.20% | 7.53% | 3.93% | 1.58% | 1.84% | 2.72% | — | — | — | |||||||
| Moderna Inc. | 53.97% | 53.02% | 49.46% | 33.75% | 21.64% | 4.71% | -10.18% | -12.85% | -13.98% | -24.46% | -32.34% | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 15.01% | 13.58% | 12.11% | 11.10% | 7.78% | 7.01% | 6.23% | 4.46% | 7.97% | 9.47% | 9.72% | 9.51% | 8.10% | 7.38% | 7.00% | 14.19% | 13.67% | 13.21% | 12.40% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 20.90% | 30.11% | 31.75% | 29.55% | 28.88% | 22.53% | 20.47% | 19.62% | 20.68% | 14.46% | 14.29% | 15.38% | 15.71% | 18.88% | 20.83% | 16.64% | 15.99% | 15.23% | 13.67% | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 8.21% | 8.20% | 8.12% | 11.64% | 12.70% | 12.02% | 9.23% | 7.62% | 6.02% | 6.25% | 6.33% | 6.33% | 6.11% | 5.71% | 5.22% | 4.66% | 4.32% | 3.98% | 3.93% | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q2 2022 Calculation
ROA = 100
× (Net earnings (loss) attributable to AbbVie Inc.Q2 2022
+ Net earnings (loss) attributable to AbbVie Inc.Q1 2022
+ Net earnings (loss) attributable to AbbVie Inc.Q4 2021
+ Net earnings (loss) attributable to AbbVie Inc.Q3 2021)
÷ Total assets
= 100 × (924 + 4,490 + 4,044 + 3,179)
÷ 143,186 = 8.83%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROA | A profitability ratio calculated as net income divided by total assets. | AbbVie Inc. ROA improved from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022. |